Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease.
about
The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthmaThe role of phosphodiesterase-5 inhibitors in prostatic inflammation: a reviewEndosomal hyperacidification in cystic fibrosis is due to defective nitric oxide-cylic GMP signalling cascadeABCD of the phosphodiesterase family: interaction and differential activity in COPDSildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow.Potential of anti-inflammatory treatment for cystic fibrosis lung disease.Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study.Allergic rhinitis, asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004.Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure.Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.Role of phosphodiesterase 5 in synaptic plasticity and memoryPhosphodiesterase V inhibition reduces airway responsiveness, but does not improve the beneficial effect of deep inspiration.Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors.Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.PDE inhibitors currently in early clinical trials for the treatment of asthma.Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.Bifunctional Drugs for the Treatment of Respiratory Diseases.Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis.Does sildenafil improve ventilatory function in asthmatic subjects?Effects of vardenafil on testicular torsion/detorsion damage: an experimental study in pigs.Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.The effects of selective and nonselective phosphodiesterase inhibitors on phagocytic cells in mice.Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis.Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.Phosphodiesterase 9 (PDE9) regulate bovine tracheal smooth muscle relaxation.Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.The protective effect of Papaverine and Alprostadil in rat testes after ischemia and reperfusion injury.
P2860
Q24804029-01E5F8A0-6FF0-475A-8031-2A549A4FDF4DQ26785428-AAF02188-94FD-422B-A51E-EEFC746549ACQ34683157-20E2681F-3F92-4973-9655-51A5350CA876Q34961511-D7EFF47A-85F9-4F12-ABC6-A7E780EEF4FEQ35545047-E572ABD1-CA4E-45C4-98E1-CC1BA71D674FQ35557381-47571F97-FC4D-4D47-ADF5-A7B1A112875BQ36067727-93DD7518-0494-403F-9BB4-5F7A9CB36942Q36080147-CC700477-1ADD-4BBB-BA28-C554ACB818FFQ36330650-60F307F3-6156-4245-9BA5-F8786BB9D29DQ36334968-9A37D11B-F6FF-41E4-9FC9-6E8977AC85B6Q37121202-6378B2AD-B051-4C8E-8DEE-DA0DA405F501Q37190561-7655A6EC-3CCE-403A-BC03-2ADC1FF58168Q37252748-05D9FCDA-1C51-4CE4-88AE-A806C153D963Q37466878-CE201564-DDE6-4FB8-A48E-5E34AE84B5E3Q38089117-E9B1E594-9AC2-4EEC-A6ED-AF8726A2E375Q38128886-D1BC0C6B-B756-4AD6-B063-EC375A075F75Q38215280-32E0DE40-087C-4510-ADBD-D09D254D351EQ38258537-7EF7DE51-9CB4-4C67-B947-0166253B9928Q38368957-943A054D-D885-4598-A47E-7C9D4B7B1AADQ38992596-324A2035-78ED-46C4-A152-CE612A750E57Q40116337-14BC854D-5B15-466F-8980-10EAD189069AQ42140599-B16CBFA3-EB9C-4AF8-A1C7-0A80FA8C15B2Q42480674-54AEDA87-466A-49FB-B8A6-FF3E00FD76B1Q43061572-83A31D51-D755-49E1-B777-2503CA300F11Q43171690-E5A46D0A-F77B-44A4-80DC-7BDF5DE3F1E3Q45285614-940430A8-DE02-4CD8-9886-24C0283734BFQ46897526-2C8AD1E3-E02E-4AA9-BD13-A4D82D965230Q46937672-7AC2982E-A40A-4A25-8314-9899DCB7BAEAQ49544797-4A18DB9B-7287-43D5-8CB7-A168900619A3Q50002026-EB836911-7AA8-4348-A6AE-6D5DC80D3885Q55157142-8B5D2D6D-C49F-4A13-83FE-B573135BB7DF
P2860
Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effect of phosphodiesterase-5 ...... mal models of airways disease.
@en
Effect of phosphodiesterase-5 ...... mal models of airways disease.
@nl
type
label
Effect of phosphodiesterase-5 ...... mal models of airways disease.
@en
Effect of phosphodiesterase-5 ...... mal models of airways disease.
@nl
prefLabel
Effect of phosphodiesterase-5 ...... mal models of airways disease.
@en
Effect of phosphodiesterase-5 ...... mal models of airways disease.
@nl
P2860
P1476
Effect of phosphodiesterase-5 ...... mal models of airways disease.
@en
P2093
Nicola Smith
Toby J Toward
P2860
P304
P356
10.1164/RCCM.200211-1372OC
P407
P577
2003-11-03T00:00:00Z